BioStem Technologies (BSEM) CAO details stock, option and RSU positions
Rhea-AI Filing Summary
BioStem Technologies, Inc. executive Michael A. Fortunato, Chief Accounting Officer, reported his initial ownership of company equity. He holds 63,460 shares of Common Stock directly. He also holds several stock options to acquire Common Stock, including 200,000 underlying shares at an exercise price of $1.07 expiring on August 16, 2027, and 100,000 underlying shares at $2.99 expiring on January 4, 2033. Additional options cover 11,582 and 2,340 underlying shares at an exercise price of $15.11 with expirations in 2035, and 38,546 underlying shares at $5.50 expiring on February 11, 2036. He also holds Restricted Stock Units that represent rights to receive 21,175, 7,760, and 31,818 shares of Common Stock, subject to multi‑year vesting schedules described in the report.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
FORTUNATO MICHAEL A
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Restricted Stock Units F7, F6 | -- | -- | -- |
| holding | Restricted Stock Units F7, F8 | -- | -- | -- |
| holding | Restricted Stock Units F7, F9 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 352,468 shares (Direct);
Restricted Stock Units — 60,753 shares (Direct);
Common Stock — 63,460 shares (Direct)
Footnotes (9)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 25% vested on January 4, 2024, the one year anniversary of the grant date, with the remaining options vesting in equal monthly installments over the subsequent three year period.
- F3. These options vest according to the following schedule: 33% vested on May 9, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. These options vest according to the following schedule: 33% will vest on October 13, 3026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F6. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F7. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F8. These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F9. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Common Stock Held: 63,460 shares
Option at $1.07: 200,000 underlying shares at $1.07
Option at $2.99: 100,000 underlying shares at $2.99
+3 more
6 metrics
Common Stock Held
63,460 shares
Directly owned Common Stock reported by the Chief Accounting Officer
Option at $1.07
200,000 underlying shares at $1.07
Stock option expiring August 16, 2027, fully vested and exercisable
Option at $2.99
100,000 underlying shares at $2.99
Stock option expiring January 4, 2033 with time‑based vesting
Options at $15.11
11,582 and 2,340 underlying shares at $15.11
Two stock option grants expiring in 2035 with quarterly vesting schedules
Option at $5.50
38,546 underlying shares at $5.50
Stock option expiring February 11, 2036 with 33% vesting after one year
RSU Awards
21,175; 7,760; 31,818 units
Restricted Stock Units, each representing a contingent right to one share
Key Terms
Stock Option (Right to Buy), Restricted Stock Units, contingent right to receive one share, vest in equal quarterly installments
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Restricted Stock Units financial
"security_title: Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest in equal quarterly installments financial
"These restricted stock units vest in equal quarterly installments over three years"
FAQ
What stock options does Michael A. Fortunato hold at BioStem Technologies (BSEM)?
He holds options over 200,000 shares at $1.07 expiring August 16, 2027; 100,000 shares at $2.99 expiring January 4, 2033; plus additional options over 11,582, 2,340, and 38,546 shares at $15.11 and $5.50 with expirations in 2035 and 2036.
How many restricted stock units does the BioStem Technologies (BSEM) CAO hold?
Michael A. Fortunato holds restricted stock units representing 21,175, 7,760, and 31,818 shares of BioStem Technologies Common Stock. Each unit represents a contingent right to receive one share, subject to multi‑year vesting schedules.
Are any of Michael A. Fortunato’s BioStem (BSEM) options already vested?
One option grant covering 200,000 underlying shares at an exercise price of $1.07 is reported as fully vested and exercisable. Other option awards vest over time, with portions vesting on specified anniversaries and then in monthly or quarterly installments.
What are the vesting terms for some BioStem Technologies (BSEM) options held by the CAO?
One option vests 25% after one year from grant and the remainder in equal monthly installments over three years. Others vest 33% after one year, with remaining portions vesting in equal quarterly installments over two years, as described in the report.
How do the BioStem Technologies (BSEM) RSUs for the CAO vest?
One RSU award granted on September 15, 2024 vests in equal quarterly installments over three years. Other RSU awards vest 33% after one year from grant, with the remaining units vesting in equal quarterly installments over the following two years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
